Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Grace Therapeutics Inc (GRCE)

Grace Therapeutics Inc (GRCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Grace Therapeutics Inc 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 USA

www.gracetx.com Employees: 6 P: 609-322-1602

Sector:

Medical

Description:

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 53,695
Enterprise Value, $K 31,565
Shares Outstanding, K 15,474
Annual Sales, $ 0 K
Annual Net Income, $ -9,570 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -940 K
EBIT, $ -12,500 K
EBITDA, $ -12,490 K
60-Month Beta 0.59
% of Insider Shareholders 11.10%
% of Institutional Shareholders 6.08%
Float, K 13,756
% Float 88.90%
Short Volume Ratio 0.15

Growth:

1-Year Return -17.92%
3-Year Return 52.59%
5-Year Return -71.98%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 90.40%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.15 on 11/13/25
Next Earnings Date 02/12/26
Earnings Per Share ttm -0.83
EPS Growth vs. Prev Qtr 28.57%
EPS Growth vs. Prev Year 54.55%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 07/10/23

GRCE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -17.47%
Return-on-Assets % -15.89%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.74
Book Value/Share 4.54
Interest Coverage -0.78
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar